Oxford, UK – 09 April 2018. OGT, The Molecular Genetics Company, has announced that on 1st April 2018 Dr John Anson who has been with the company since 2006 as EVP of R&D took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board. In addition, as part of the company’s increasing focus on diagnostics following its acquisition by Sysmex Corporation (Sysmex), OGT has appointed Paul Kenny in a new regulatory position—EVP of Regulatory and Medical Affairs. This new appointment will equip the company to successfully navigate the ever-evolving IVD regulatory landscape.
Dr Mike Evans has been with the company since 2005 during which time he spearheaded OGT’s transformation from a microarray licensing-led business model to a highly successful molecular genetics products business. During his tenure, Dr Evans oversaw the successful acquisition and incorporation of OGT’s CytoCell® fluorescence in situ hybridisation (FISH) probes business in 2014—beginning the transformation into a diagnostics company. In 2017, Dr Evans led the company through the smooth acquisition by Sysmex, a leading provider of haematology and in vitro diagnostics products.
Dr Anson, has been responsible for OGT’s successful alignment with market growth in molecular genetics and the move towards molecular diagnostics. Dr Anson led R&D teams that are now collaborating with Sysmex to develop an automated system for FISH testing that combines Sysmex’s instrumentation technology with OGT’s high-quality FISH reagent development expertise. As CEO, Dr Anson will lead the company in its next chapter and help realise the opportunities of bringing together OGT’s innovation and expertise in genetic assays with Sysmex’s instrument development and in vitro diagnostic capabilities.
Dr Anson CEO, commented, “I am looking forward to picking up the mantle from Mike to steer OGT in its next growth phase as part of Sysmex, and the successful integration of our portfolios. We have already identified many great opportunities for product development combining our reagents expertise with Sysmex’s instruments. There are also excellent commercial synergies, further expanding our market access into molecular diagnostics— which is exactly where we want to grow.”
With the increasing focus on diagnostics, the appointment of Paul Kenny as EVP of Regulatory and Medical Affairs ensures the company is well positioned to handle all Regulatory Affairs matters as the regulatory landscape evolves, including clearance and post market surveillance in global markets. Paul comes to OGT from immunodiagnostic company, The Binding Site, where he was Head of Regulatory Affairs for five years, and has wide-ranging Regulatory Affairs expertise gained at The Binding Site, Olympus and Ortho Clinical Diagnostics.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
New SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results.Read